David J. Margolis
VerifiedUniversity of Pennsylvania · Rehabilitation Medicine
Active 1942–2025
About
David J. Margolis, MD, MSCE, Ph.D, is the Gerald R. Lazarus Professor at the University of Pennsylvania Perelman School of Medicine. He serves as an Attending Physician in the Department of Dermatology and is a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics. Dr. Margolis is a member of the University of Pennsylvania Cancer Center, the Graduate Group in Epidemiology and Biostatistics, the Institute for Diabetes, Obesity and Metabolism (IDOM), and the Institute for Translational Medicine and Therapeutics (ITMAT). His research expertise includes epidemiology, clinical trials, pharmacoepidemiology, wound repair, and chronic wounds, with a clinical focus on dermatology and chronic wounds.
Research topics
- Immunology
- Biology
- Neuroscience
- Pathology
- Medicine
- Cell biology
Selected publications
Journal of the American Academy of Dermatology · 2025-09-01
articleSenior authorInternational Journal of Dermatology · 2025-04-26
articleOpen accessSenior authorIRB Approval Status: Study was approved by IMRD, the Scientific Review Committee (SRC) for UK Ethics as protocol number 22SRC042 and the University of Pennsylvania Institutional Review Board (IRB). Z.C.C.F. has received research grants from Lilly, LEO Pharma, Brexogen, Regeneron, Sanofi, Tioga, and Vanda for work related to atopic dermatitis and from Menlo Therapeutics and Galderma for work related to prurigo nodularis. She has also served as a consultant for the Asthma and Allergy Foundation of America, National Eczema Association, AbbVie, Incyte Corporation, and Pfizer; and received honoraria for CME work in Atopic Dermatitis sponsored by education grants from Regeneron/Sanofi and Pfizer and from Beirsdorf for work related to skin cancer and sun protection. E.A.G. is on the scientific advisory board for L'Oreal Advanced Research and is a consultant for Unilever. A.R., N.M., O.H., and D.J.M. have no relevant conflicts of interest. Data available within the article.
Management of Diabetic Wounds: Expert Panel Consensus Statement
Advances in Wound Care · 2025-08-20 · 3 citations
articleOpen accessSIGNIFICANCE: The Wound Healing Foundation recognized the need for consensus-based unbiased recommendations for the treatment of wounds. Consensus statements on the treatment of chronic wounds and acute wounds have been developed and published previously. The current publication on diabetic wounds represents the next step in this process. Diabetic wounds constitute a major problem. Population-based and meta-analytic studies indicate that the presence of foot wounds in patients with diabetes increases their mortality risk by more than twofold. The management of diabetic wounds requires consistent and evidence-driven intervention to achieve optimal clinical outcomes. This consensus statement provides the clinician with the necessary foundational approaches to the causes, diagnosis, and therapeutic management of diabetic wounds. Presented in a structured format, this is a useful guide for clinicians and learners in all patient care settings. RECENT ADVANCES: Continuous glucose monitoring and other new tools have facilitated better diabetes management and the management of associated wounds. Diabetic limb salvage should focus on achieving and optimizing function for the patient with diabetes rather than preserving limb tissue at all costs. CRITICAL ISSUES: Successful management of diabetic wounds requires a multidisciplinary approach encompassing comprehensive assessment, timely intervention, and collaborative care by the wound clinician with providers who can address critical aspects to achieve healing, including careful management of blood glucose levels, optimization of off-loading and physical therapy, assessment and treatment of limb ischemia, control and prevention of wound infection, and optimal pain management. FUTURE DIRECTIONS: Emerging treatments offer hope and promise, but the heterogenicity of diabetic wounds poses a challenge to performing good studies, which will be necessary to advance new treatments for diabetic wounds.
Journal of Investigative Dermatology · 2025-07-21 · 1 citations
articleJournal of Investigative Dermatology · 2025-07-21
articleOpen accessWound Repair and Regeneration · 2025-11-01
articleDiabetic foot ulcers (DFUs) are common and difficult to treat because the mechanisms behind unsuccessful responses to treatment are poorly understood. The goals of this study were to identify differences in healing and non-healing human DFUs using debrided tissue samples and to identify possible biomarkers of non-healing. First, DFU tissue samples collected over 12 weeks of treatment from 27 subjects (n = 12 healing and n = 15 non-healing) were analysed using a focused panel of 227 inflammation and wound healing-related human genes and 16S ribosomal RNA amplicon sequence to identify microbial species. Gene expression and correlation with microbial species differed between healing and non-healing DFUs. While no individual genes analysed at the initial time point could accurately predict healing outcome 12 weeks later, several 2-gene ratios were highly accurate. The ratio of C3AR1/CCL22 predicted healing outcome in the discovery cohort with an area under the receiver operator characteristic (ROC) curve (AUC) of 0.96. The AUC was 0.80 when tested on 74 unique samples collected at later time points from the discovery cohort, and the AUC was 0.69 when validated in a completely independent cohort of n = 51 subjects and using quantitative reverse transcription polymerase chain reaction (qRTPCR) as a more translational method of detection. The AUC increased to 0.75 when initial wound area was included. Overall, the results suggest that differences in inflammation contribute to differential healing outcomes in human chronic DFUs, and associated biomarkers may be used to predict healing outcome to guide treatment decisions.
Journal of the American Academy of Dermatology · 2025-02-01 · 1 citations
articleOpen accessSenior authorJournal of Hepatology · 2025-05-01 · 2 citations
articleMendelian Randomization for Dermatology Research
JAMA Dermatology · 2025-02-05 · 4 citations
articleThis JAMA Network Insight describes the use of mendelian randomization, including key assumptions that must be met, in dermatology research.
Medicare coverage of home phototherapy units for cutaneous T-cell lymphoma versus psoriasis
Journal of the American Academy of Dermatology · 2025-10-17
article
Recent grants
Collagen turnover-stimulated gene delivery to enhance chronic wound repair
NIH · $1.4M · 2016–2022
Cutaneous Phenomics and Transcriptomics
NIH · $16.0M · 2016–2026
NIH · $384k · 2004
Penn Dermatology Research Training Program
NIH · $9.9M · 1983–2029
NIH · $2.7M · 2017
Frequent coauthors
- 109 shared
Ole Hoffstad
University of Pennsylvania
- 93 shared
Jeffrey S. Gerber
Children's Hospital of Philadelphia
- 92 shared
Joshua P. Metlay
Harvard University
- 83 shared
Katherine E. Fleming-Dutra
Kaiser Permanente
- 83 shared
Jonathan A. Finkelstein
Kaiser Permanente
- 83 shared
Thomas M. File
- 83 shared
Jeffrey A. Linder
Northwestern University
- 83 shared
Daniel Merenstein
Georgetown University Medical Center
Labs
David J. Margolis LabPI
Awards & honors
- Gerald R. Lazarus Professor
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with David J. Margolis
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup